Clinical Trial

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-29; most recent amendment 2025-08-12.
Status change: Not Yet Recruiting → Recruiting 2025-07-14
Trial Details
NCT Number NCT06952478
Lead Sponsor Celltrion
Conditions Refractory or Relapsed Multiple Myeloma
Enrollment 486 participants
Start Date 2025-08-12
Primary Completion 2027-11-15 (estimated)
Study Completion 2029-06-25 (estimated)
Updated on ClinicalTrials.gov 2025-08-15